title: Centrosome abnormalities in ovarian cancer.
abstract: Centrosome abnormalities have been found in various cancer types and are thought to be involved in early development of cancer and/or progression. The contribution of centrosome abnormalities to ovarian tumorigenesis has not been previously evaluated. We sought to determine whether centrosome dysfunction occurs in ovarian tumorigenesis, and whether it could be used as an indicator of early neoplastic changes in ovarian surface epithelium (OSE). Primary cultures of normal OSE and ovarian tumors, as well as paraffin-embedded normal ovaries and ovarian tumors of different stages, were used for immunostaining with a gamma-tubulin antibody. Centrosomes were considered abnormal if there were more than 2 per cell, if their sizes were greater than 2-fold of a normal centrosome, and/or if they were abnormal in shape. Centrosomes in normal tissue were uniform in size, whereas centrosomes in ovarian tumors tended to be abnormal in size, number and shape. On average, 4.7% of cells in 5 primary normal OSE cultures had more than 2 centrosomes, whereas 14.1% of primary cells from 5 ovarian tumors displayed centrosome abnormalities (p = 0.008). Centrosome abnormalities were present in 60.9% of stage I (n = 23), 83.3% of stage II (n = 30) and all stage III (n = 10) paraffin-embedded ovarian tumor samples examined, but not in normal tissues. In addition, centrosome abnormalities occurred more frequently in ovarian tumors with higher grade and aggressive serous subtype. This is the first demonstration that centrosome abnormalities occur in ovarian tumors. Centrosome dysfunction may be an early event in ovarian carcinogenesis and involved in ovarian tumor progression.
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Magee-Womens Research Institute, Pittsburgh, PA 15213, USA. rsilh@mwri.magee.edu <rsilh@mwri.magee.edu>
authors.forename: Lih-Ching
authors.initials: LC
authors.lastname: Hsu
authors.forename: Malathy
authors.initials: M
authors.lastname: Kapali
authors.forename: Julie A
authors.initials: JA
authors.lastname: DeLoia
authors.forename: Holly H
authors.initials: HH
authors.lastname: Gallion
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D015153:Blotting, Western; D018269:Carcinoma, Endometrioid / Q000235:genetics / Q000473:pathology; D018385:Centrosome / Q000737:chemistry / Q000473:pathology*; D002869:Chromosome Aberrations; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000473:pathology; D004847:Epithelial Cells / Q000166:cytology; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology*; D010053:Ovary / Q000166:cytology / Q000378:metabolism; D011003:Ploidies; D014407:Tumor Cells, Cultured